Rankings
▼
Calendar
ESLA Q4 2021 Earnings — Estrella Immunopharma, Inc. Revenue & Financial Results | Market Cap Arena
ESLA
Estrella Immunopharma, Inc.
$53M
Q4 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$105,893
Net Income
-$105,893
EPS (Diluted)
$-0.00
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$293,300
Free Cash Flow
-$293,300
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$46M
Total Liabilities
$2M
Stockholders' Equity
$44M
Cash & Equivalents
$478,868
← FY 2021
All Quarters
Q1 2022 →
